Peldacyn Use In Pregnancy & Lactation

Capsule: Pregnancy: Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were approximately 30% of maternal blood concentrations.
In clinical trails with pregnant women, the systematic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.
Clindamycin should be used in pregnancy only if clearly needed.
Oral and subcutaneous reproductive toxicity studies in rats and rabbits revealed no evidence of impaired fertility or harm to the foetus due to clindamycin, except at doses that caused maternal toxicity. Animal reproduction studies are not always predictive of human response.
Lactation: Orally and parenterally administered clindamycin has been reported to appear in human breast milk in ranges from 0.7 to 3.8 μg/mL. Because of the potential for serious adverse reactions in nursing infants, clindamycin should not be taken by nursing mothers.
Fertility: Fertility studies in rats treated orally with clindamycin revealed no effects on fertility or mating ability.
Solution for Injection: Use in Pregnancy: Safety for use in pregnancy has not been established.
Use in Lactation: Since clindamycin has been reported to be excreted in breast milk in ranges of 0.7-3.8 mcg/mL, it should not be used during lactation.